Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current therapy of trypanosomiasis]

F Doua1, F Boa Yapo

  • 1Projet de Recherches cliniques sur la trypanosomiase, Daloa.

Bulletin De La Societe De Pathologie Exotique (1990)
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.

Antimicrobial agents and chemotherapy·2014
Same author

The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness.

European journal of clinical pharmacology·2004
Same author

Human African trypanosomiasis: quantitative and qualitative assessment of intrathecal immune response.

European journal of neurology·2003
Same author

[Geographic distribution of trypanosomiasis treated in Ivory Coast from 1993 to 2000].

Bulletin de la Societe de pathologie exotique (1990)·2003
Same author

[Human African trypanosomiasis in Ivory Coast: biological characteristics after treatment. 812 cases treated in the Daloa focus (Ivory Coast)].

Bulletin de la Societe de pathologie exotique (1990)·2003
Same author

IgM quantification in the cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test.

Tropical medicine & international health : TM & IH·2002

New treatments for Human African Trypanosomiasis (HAT) include early pentamidine and promising DFMO therapy. Novel compounds show efficacy, but current HAT chemotherapy relies on established drugs pending further trials.

Area of Science:

  • Medical Parasitology
  • Tropical Medicine
  • Pharmacology

Background:

  • Human African Trypanosomiasis (HAT) presents significant treatment challenges.
  • Current chemotherapy involves pentamidine, suramin, and melarsoprol, each with limitations.
  • Emerging therapies and compounds offer potential improvements in efficacy and safety.

Purpose of the Study:

  • To review existing and novel chemotherapeutic agents for HAT.
  • To evaluate new treatment strategies and drug candidates.
  • To inform future HAT treatment protocols.

Main Methods:

  • Review of available literature on HAT chemotherapy.
  • Analysis of current drug administration protocols and pharmacokinetic data.
  • Assessment of preliminary clinical trial data for new compounds.

Related Experiment Videos

Main Results:

  • Pentamidine administration in early neurological stages offers a new treatment approach.
  • An alternative melarsoprol protocol may reduce relapse rates and hospital stays.
  • Short-term DFMO therapy shows encouraging efficacy and tolerance, potentially offering a cost-effective option, especially against resistant strains.
  • New compounds MLD 73811 and IMOL 881 demonstrate trypanocidal activity.

Conclusions:

  • DFMO is a promising candidate for HAT treatment due to its efficacy, tolerance, and potential cost-effectiveness.
  • Further randomized clinical trials are necessary to validate new melarsoprol protocols and DFMO efficacy.
  • Novel compounds like MLD 73811 and IMOL 881 warrant further development for HAT treatment.
  • Classical trypanocides remain the cornerstone of HAT treatment until new agents are widely available.